ABSTRACT Introduction As utilization of MISTs for the treatment of BPH increases, physicians and patients should seek to understand not only long-term symptom outcomes, but also factors that may drive high satisfaction during the recovery period. Objective This new sub-analysis evaluates factors that may influence satisfaction in the early recovery period after undergoing Rezum Water Vapor Therapy (Rezum) or UroLift Prostatic Urethral Lift (PUL). Methods Within 2 months post-procedure, 30 PUL and 23 Rezum patients completed a questionnaire detailing their experience. Highly Satisfied patients achieved a pooled score of ≥3 on two questions on the subject of satisfaction (satisfaction with the effect of the procedure on urinary symptoms; satisfaction with speed and ease of recovery). For each question, a score of <0 = dissatisfaction and a score of +2 = high satisfaction. Outcomes were compared between all Highly Satisfied vs. all Dissatisfied patients, and between PUL vs. Rezum patients. Results Highly Satisfied patients in the early recovery period after either procedure reported significantly better absolute IPSS (8.0 vs. 24.3, p<0.0001) and QoL (1.0 vs. 4.6, p<0.0001) compared to Dissatisfied patients. Catheter duration was shorter for Highly Satisfied patients (1.9d) compared to Dissatisfied patients (5.6d, p=0.02). Highly Satisfied patients experienced lower rates of interference by their urinary symptoms with activities related to sports, entertainment, and community, and experienced less impact of recovery on work (p-value = 0.002). Within this early recovery timeframe, outcomes associated with increased satisfaction (IPSS, QoL, catheter duration, interference by urinary symptoms with sports, entertainment, and community activities) were better for PUL vs. Rezum patients (respective p-values: 0.001, 0.04, <0.001, 0.007, 0.01, 0.04). Conclusions Better absolute IPSS and QoL scores, less interference by urinary symptoms, and shorter duration of catheterization in the early recovery period appear to be factors which correspond to satisfaction in this population of MIST patients; these factors demonstrate superior outcomes for PUL patients compared to Rezum. Disclosure No